Nexalin Technology (NXL) Change in Accured Expenses (2022 - 2026)
Nexalin Technology (NXL) recorded quarterly Change in Accured Expenses of -$2489.0 in Q1 2026, down 100.78% quarter-over-quarter from $318723.0 in Q4 2025, and down 195.84% on a YoY basis from $2597.0 in Q1 2025.
Nexalin Technology (NXL) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Nexalin Technology's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$2489.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 195.84% year-over-year to -$2489.0; the TTM figure through Mar 2026 stood at $246923.0 (up 556.2% YoY), while the FY2025 annual figure was $252009.0, up 94.66% from the prior year.
- Change in Accured Expenses was -$2489.0 for Q1 2026 at Nexalin Technology, down from $318723.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $318723.0 in Q4 2025 to a low of -$230747.0 in Q2 2024.
- Historically, Change in Accured Expenses has averaged $18502.9 across 5 years, with a median of $5973.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 316.82% in 2023, then plunged 3963.17% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $97322.0 in 2022, then tumbled by 336.95% to -$230607.0 in 2023, then jumped by 211.83% to $257898.0 in 2024, then gained by 23.58% to $318723.0 in 2025, then slumped by 100.78% to -$2489.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$2489.0 (Q1 2026), $318723.0 (Q4 2025), and -$47973.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 157.80 Bn | 151.14 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.54 Bn | 112.66 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 103.44 Bn | 95.27 Bn | 5.76 Bn | 703.00 Mn |
| 4 | Boston Scientific | 72.38 Bn | 71.17 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 49.76 Bn | 46.09 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Dexcom | 29.53 Bn | 28.42 Bn | 750.30 Mn | 145.10 Mn |
| 7 | GE HealthCare Technologies | 29.51 Bn | 27.44 Bn | 1.98 Bn | -250.00 Mn |
| 8 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 21.07 Mn |
| 9 | Steris | 20.69 Bn | 20.27 Bn | 697.10 Mn | 74.30 Mn |
| 10 | Nexalin Technology | 9.98 Mn | 7.27 Mn | 13,133.00 | -2,489.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,489.00 |
| Mar 31, 2026 | -2,489.00 |
| Dec 31, 2025 | 318,723.00 |
| Dec 31, 2025 | 318,723.00 |
| Sep 30, 2025 | -47,973.00 |
| Sep 30, 2025 | -47,973.00 |
| Jun 30, 2025 | -21,338.00 |
| Jun 30, 2025 | -21,338.00 |
| Mar 31, 2025 | 2,597.00 |
| Mar 31, 2025 | 2,597.00 |
| Dec 31, 2024 | 257,898.00 |
| Dec 31, 2024 | 257,898.00 |
| Sep 30, 2024 | 7,881.00 |
| Sep 30, 2024 | 7,881.00 |
| Jun 30, 2024 | -230,747.00 |
| Jun 30, 2024 | -230,747.00 |
| Mar 31, 2024 | 94,429.00 |
| Mar 31, 2024 | 94,429.00 |
| Dec 31, 2023 | -230,607.00 |
| Dec 31, 2023 | -230,607.00 |